
Tanezumab reduces osteoarthritic knee pain but increases adverse events

Tanezumab reduces osteoarthritic knee pain but increases adverse events
Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
J Pain. 2012 Aug;13(8):790-8. doi: 10.1016/j.jpain.2012.05.006. Epub 2012 Jul 10.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
690 patients with osteoarthritis of the knee were randomized to receive 2.5 mg of tanezumab, 5 mg of tanezumab, 10 mg of tanezumab, or a placebo. The results of the study indicate that the patients treated with tanezumab experienced a significant improvement in knee pain and function, but also an incidence of adverse events of 55 to 60%. It should be noted that the tanezumab osteoarthritis clinica...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Learn about our AI Driven
High Impact Search Feature

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.